New immunotherapy combination for advanced esophageal cancer after prior treatment
Part of Cancer, Digestive system clinical trials.
This trial is testing a new immunotherapy drug (QL1706) combined with an anti-inflammatory drug (celecoxib) for advanced esophageal cancer that has progressed after previous immunotherapy. It may help slow down tumor growth and give you more treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced esophageal cancer (type called squamous cell carcinoma) that cannot be removed by surgery and has come back or spread.
- You must have already tried a PD-1 or PD-L1 immunotherapy medicine (like pembrolizumab or nivolumab) for at least 6 months, and your cancer grew while on it.
- You need to have at least one tumor that can be measured on a scan.
- You must be able to swallow pills.
- You need to be in fairly good health (able to do light activities) and have adequate organ function (kidney, liver, blood counts). You should not have serious heart problems or active infections like tuberculosis or hepatitis B/C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
This trial tests a new drug combination (SKB500 plus other treatments) for people with advanced esophageal squamous cell carcinoma. It aims to see if the combination is safe and effective for those who have had little or no prior treatment.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
This study tests a new treatment for advanced or metastatic esophageal cancer that has not responded to previous chemotherapy. It aims to see if this treatment can help slow down the cancer or shrink tumors.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.